This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Login or create an account to see restricted content
Login or RegisterThe TECOS CVOT assessed the cardiovascular safety of sitagliptin in patients with type 2 diabetes and prior CV disease. This module details the results.